Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6766 to 6780 of 7707 results

  1. Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

    Discontinued [GID-TA10353]

  2. Contusugene ladenovec for the treatment of recurrent unresectable squamous cell carcinoma of the head and neck [ID76]

    Discontinued [GID-TAG407]

  3. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued [GID-TA10318]

  4. Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071]

    Discontinued [GID-TA10110]

  5. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued [GID-TA10697]

  6. Peramivir for treating influenza [ID828]

    Discontinued [GID-TA10155]

  7. Lung cancer (non-small cell) - afatinib [ID357]

    Discontinued [GID-TAG422]

  8. Workplace health for employees with disabilities and long-term conditions

    Discontinued [GID-PHG58]

  9. Inpatient mental health settings

    Discontinued [GID-SGWAVE0701]

  10. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued [GID-TA10154]

  11. Furosemide micro-pump for treating oedema associated with heart failure (ID1061)

    Discontinued [GID-TA10179]

  12. Accident and emergency departments

    Discontinued [GID-SGWAVE0762]